Abstract
Tumor cell resistance to multiple « natural product » anticancer drugs, known as multidrug resistance (MDR), is now a well-documented phenomenon, and some excellent reviews have recently summarized its pharmacology and cell and molecular biology [1–5]. Several types of natural product MDR have been described: one is associated with P-glycoprotein overexpression (Pgp-MDR) [1–5], another with alterations in DNA topoisomerase II (at-MDR) [6], and a third with features similar to Pgp-MDR but without Pgp overexpression [7, 8]. Although Pgp-MDR appears to have clinical correlates, we do not yet know about the clinical relevance of other forms of MDR.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beck WT (1987) The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879–2887
Moscow JA, Cowan KH (1988) Multidrug resistance. J Natl Cancer Inst 80: 14–20
Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multi-drug resistance. Ann Rev Biochem 58: 137–171
Van der Bliek AM, Borst P (1989) Multidrug resistance. Adv Cancer Res 52: 165–203
Roninson IB (1991) Molecular and cellular biology of multidrug resistance in tumor cells. Plenum Publishing Corp, New York (in press)
Beck WT, Danks MK (1991) Multidrug resistance associated with alterations in topoisomerase II. In: Potmesil M, Kohn K (Eds) DNA topoisomerases in cancer chemotherapy. Oxford University Press, New York (in press)
Hindenburg AA, Gervasoni JE Jr, Krishna S, Stewart VJ, Rosado M, Lutzky J, Bhalla K, Baker MA, Taub RN (1989) Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res 49: 4607–4614
McGrath T, Center MS (1988) Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 48: 3959–3963
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieker M, Crossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116–124
Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, VonHoff DD, Roninson IB (1990) Proc Nati Acad Sci USA 87: 7160–7164
Chan HSL, Thorner PS, Haddad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689–704
Safa AR, Glover CJ, Meyers MB, Biedler JL, Felsted RL (1986) Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem 261: 6137–6140
Qian X-d, Beck WT (1990) Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug resistant human leukemic cell lines. Cancer Res 50: 1132–1137
Qian X-d, Beck WT (1990) Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts. J Biol Chem 265: 18753–18756
Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT (1989) Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86: 5128–5132
Danks MK, Yalowich JC, Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47: 1297–1301
Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of « atypical » multidrug-resistant human leukemia cells. Cancer Res 47: 5455–5460
Danks MK, Schmidt CA, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861–8869
Danks MK, Schmidt CA, Deneka DA, Beck WT (1989) Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide. Cancer Commun 1: 101–109
Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F, Rosen N, Fojo AT (1989) Modulation of the expression of a multidrug resistance gene (mdr-1/Pglycoprotein) by differentiating agents. J Biol Chem 264: 18031–18040
Fernandes DJ, Danks MK, Beck WT (1990) Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 29: 4235–4241
Trask DK, DiDonato JA, Muller MT (1984) Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. EMBO J 3: 671–676
Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M (1989) Characterization of an amsacrine-resistant line of human leukemia cells. J Biol Chem 264: 16411–16420
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag France
About this paper
Cite this paper
Beck, W.T., Danks, M.K., Funabiki, T. (1991). Issues in multidrug resistance. In: Banzet, P., Holland, J.F., Khayat, D., Weil, M. (eds) Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy. Springer, Paris. https://doi.org/10.1007/978-2-8178-0782-9_93
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0782-9_93
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0784-3
Online ISBN: 978-2-8178-0782-9
eBook Packages: Springer Book Archive